JP2013528204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528204A5 JP2013528204A5 JP2013513758A JP2013513758A JP2013528204A5 JP 2013528204 A5 JP2013528204 A5 JP 2013528204A5 JP 2013513758 A JP2013513758 A JP 2013513758A JP 2013513758 A JP2013513758 A JP 2013513758A JP 2013528204 A5 JP2013528204 A5 JP 2013528204A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methylmorpholin
- methylsulfonimidoyl
- amine
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- -1 3-methylmorpholin-4-yl Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- YXSYJGJKBNBZLQ-BRRNQIAESA-N 1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(N2C3=CC=CC=C3N=C2N)=N1 YXSYJGJKBNBZLQ-BRRNQIAESA-N 0.000 claims 1
- YXSYJGJKBNBZLQ-OSXTUODASA-N 1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@@](C)(=N)=O)=NC(N2C3=CC=CC=C3N=C2N)=N1 YXSYJGJKBNBZLQ-OSXTUODASA-N 0.000 claims 1
- WUJFVGIVMGNTPV-FZAOIFNZSA-N 4-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=C(F)C=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@@](C)(=N)=O)CC1 WUJFVGIVMGNTPV-FZAOIFNZSA-N 0.000 claims 1
- WUJFVGIVMGNTPV-RZQXLCLMSA-N 4-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=C(F)C=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CC1 WUJFVGIVMGNTPV-RZQXLCLMSA-N 0.000 claims 1
- HQFFRTPOWLGAIX-FZAOIFNZSA-N 4-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=C(F)C=CC=C2N1C(N=C(C=1)C(C)(C)[S@@](C)(=N)=O)=NC=1N1CCOC[C@H]1C HQFFRTPOWLGAIX-FZAOIFNZSA-N 0.000 claims 1
- HQFFRTPOWLGAIX-RZQXLCLMSA-N 4-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=C(F)C=CC=C2N1C(N=C(C=1)C(C)(C)[S@](C)(=N)=O)=NC=1N1CCOC[C@H]1C HQFFRTPOWLGAIX-RZQXLCLMSA-N 0.000 claims 1
- IVKZEHQGPBBLPD-FZAOIFNZSA-N 5-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC(F)=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@@](C)(=N)=O)CC1 IVKZEHQGPBBLPD-FZAOIFNZSA-N 0.000 claims 1
- FGTJUHKILGGMAK-FZAOIFNZSA-N 5-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC(F)=CC=C2N1C(N=C(C=1)C(C)(C)[S@@](C)(=N)=O)=NC=1N1CCOC[C@H]1C FGTJUHKILGGMAK-FZAOIFNZSA-N 0.000 claims 1
- FGTJUHKILGGMAK-RZQXLCLMSA-N 5-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC(F)=CC=C2N1C(N=C(C=1)C(C)(C)[S@](C)(=N)=O)=NC=1N1CCOC[C@H]1C FGTJUHKILGGMAK-RZQXLCLMSA-N 0.000 claims 1
- AORKOLDGMLWWPG-RZQXLCLMSA-N 6-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=C(F)C=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CC1 AORKOLDGMLWWPG-RZQXLCLMSA-N 0.000 claims 1
- PSIPSQLSHTYKJT-FZAOIFNZSA-N 6-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=C(F)C=C2N1C(N=C(C=1)C(C)(C)[S@@](C)(=N)=O)=NC=1N1CCOC[C@H]1C PSIPSQLSHTYKJT-FZAOIFNZSA-N 0.000 claims 1
- PSIPSQLSHTYKJT-RZQXLCLMSA-N 6-fluoro-n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=C(F)C=C2N1C(N=C(C=1)C(C)(C)[S@](C)(=N)=O)=NC=1N1CCOC[C@H]1C PSIPSQLSHTYKJT-RZQXLCLMSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- OOEYPUFPMHMEAP-IZPCHGGPSA-N imino-[1-[2-(1h-indol-4-yl)-6-[(3r)-3-methylmorpholin-4-yl]pyrimidin-4-yl]cyclopropyl]-methyl-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3C=CC=2)=N1 OOEYPUFPMHMEAP-IZPCHGGPSA-N 0.000 claims 1
- OOEYPUFPMHMEAP-ONSXPEOJSA-N imino-[1-[2-(1h-indol-4-yl)-6-[(3r)-3-methylmorpholin-4-yl]pyrimidin-4-yl]cyclopropyl]-methyl-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@@](C)(=N)=O)=NC(C=2C=3C=CNC=3C=CC=2)=N1 OOEYPUFPMHMEAP-ONSXPEOJSA-N 0.000 claims 1
- IFKRIACODANJFM-FTDQSSOUSA-N imino-[4-[2-(1h-indol-4-yl)-6-[(3r)-3-methylmorpholin-4-yl]pyrimidin-4-yl]oxan-4-yl]-methyl-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CCOCC2)[S@@](C)(=N)=O)=NC(C=2C=3C=CNC=3C=CC=2)=N1 IFKRIACODANJFM-FTDQSSOUSA-N 0.000 claims 1
- OHUHVTCQTUDPIJ-MUWSIPGASA-N imino-methyl-[1-[6-[(3r)-3-methylmorpholin-4-yl]-2-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-MUWSIPGASA-N 0.000 claims 1
- DTTJKLNXNZAVSM-RNHBAAACSA-N imino-methyl-[1-[6-[(3r)-3-methylmorpholin-4-yl]-2-(1h-pyrrolo[2,3-c]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)S(C)(=N)=O)=NC(C=2C=3C=CNC=3C=NC=2)=N1 DTTJKLNXNZAVSM-RNHBAAACSA-N 0.000 claims 1
- FEFZJKWFEQKDHO-KHXSAUHESA-N imino-methyl-[[6-[(3r)-3-methylmorpholin-4-yl]-2-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]methyl]-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 FEFZJKWFEQKDHO-KHXSAUHESA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- JESNSKPPMWEWAT-JKGBWWFKSA-N n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CC1 JESNSKPPMWEWAT-JKGBWWFKSA-N 0.000 claims 1
- JESNSKPPMWEWAT-YSVRNHBLSA-N n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@@](C)(=N)=O)CC1 JESNSKPPMWEWAT-YSVRNHBLSA-N 0.000 claims 1
- LRIFUSYFLXZCKX-JKGBWWFKSA-N n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=C(C=1)C(C)(C)[S@](C)(=N)=O)=NC=1N1CCOC[C@H]1C LRIFUSYFLXZCKX-JKGBWWFKSA-N 0.000 claims 1
- LRIFUSYFLXZCKX-YSVRNHBLSA-N n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=C(C=1)C(C)(C)[S@@](C)(=N)=O)=NC=1N1CCOC[C@H]1C LRIFUSYFLXZCKX-YSVRNHBLSA-N 0.000 claims 1
- YIASZZUGUQHGBB-JTJFVBHCSA-N n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[4-(methylsulfonimidoyl)oxan-4-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CCOCC1 YIASZZUGUQHGBB-JTJFVBHCSA-N 0.000 claims 1
- YIASZZUGUQHGBB-RZCFMFBHSA-N n-methyl-1-[4-[(3r)-3-methylmorpholin-4-yl]-6-[4-(methylsulfonimidoyl)oxan-4-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@@](C)(=N)=O)CCOCC1 YIASZZUGUQHGBB-RZCFMFBHSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35371310P | 2010-06-11 | 2010-06-11 | |
| US61/353,713 | 2010-06-11 | ||
| PCT/GB2011/051074 WO2011154737A1 (en) | 2010-06-11 | 2011-06-09 | Morpholino pyrimidines and their use in therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528204A JP2013528204A (ja) | 2013-07-08 |
| JP2013528204A5 true JP2013528204A5 (https=) | 2014-07-03 |
| JP5721821B2 JP5721821B2 (ja) | 2015-05-20 |
Family
ID=44168987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513758A Active JP5721821B2 (ja) | 2010-06-11 | 2011-06-09 | モルホリノピリミジンおよび治療におけるそれらの使用 |
Country Status (38)
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| WO2018029117A1 (en) * | 2016-08-10 | 2018-02-15 | Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) | New atr inhibitors for the use in cancer therapy |
| JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
| TW201840319A (zh) | 2017-02-24 | 2018-11-16 | 德商拜耳廠股份有限公司 | Atr激酶抑制劑與鐳-223鹽之組合 |
| WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| WO2019014618A1 (en) | 2017-07-13 | 2019-01-17 | Board Of Regents, University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| US11690911B2 (en) | 2017-08-04 | 2023-07-04 | Bayer Aktiengesellschaft | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors |
| JP7290627B2 (ja) * | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| EP3679041B1 (en) | 2017-09-08 | 2022-07-06 | Newave Pharmaceutical Inc. | Substituted pyrrolopyridines as atr inhibitors |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| EP3720973A1 (en) | 2017-12-08 | 2020-10-14 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
| GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| DK3753937T3 (da) * | 2018-02-07 | 2024-02-12 | Wuxi Biocity Biopharmaceutics Co Ltd | Atr-hæmmer og anvendelse deraf |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2020078788A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| AU2019373416A1 (en) | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| IL283901B2 (en) * | 2018-12-18 | 2025-03-01 | Astrazeneca Ab | Process and intermediates for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b]pyridine |
| MX2021008984A (es) | 2019-01-30 | 2021-09-08 | Felicamed Biotechnology Co Ltd | Inhibidor jak y metodo de preparacion del mismo. |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN118619944A (zh) | 2019-06-06 | 2024-09-10 | 北京泰德制药股份有限公司 | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 |
| GB201908536D0 (en) * | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
| CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
| PT4011881T (pt) | 2019-08-06 | 2025-03-05 | Wuxi Biocity Biopharmaceutics Co Ltd | Formas cristalinas de um inibidor da atr e sua utilização |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| TW202128690A (zh) * | 2019-11-21 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用 |
| CN112939966B (zh) * | 2019-12-10 | 2023-03-24 | 武汉光谷亚太医药研究院有限公司 | 嘧啶衍生物、其制备及应用 |
| TW202140474A (zh) * | 2020-01-17 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用 |
| US20240150333A1 (en) * | 2020-03-20 | 2024-05-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Taf1 inhibitors |
| IL297842A (en) | 2020-05-11 | 2023-01-01 | Astrazeneca Ab | ATR inhibitors for cancer treatment |
| EP4159734B1 (en) * | 2020-05-29 | 2025-08-13 | Wuxi Life Fountain Biotech Co., Ltd. | Fluoropyrrolopyridine compound and application thereof |
| CN111646985A (zh) * | 2020-06-01 | 2020-09-11 | 江苏集萃分子工程研究院有限公司 | 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法 |
| IL299368A (en) * | 2020-06-24 | 2023-02-01 | Astrazeneca Uk Ltd | A combination of an antibody-drug conjugate and an ATR inhibitor |
| IL299804A (en) * | 2020-07-13 | 2023-03-01 | Beijing Tide Pharmaceutical Co Ltd | Pyrazolopyrimidine compounds for use as ATR kinase inhibitors |
| WO2022094218A1 (en) * | 2020-10-29 | 2022-05-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Process for the preparation of heteroaryl-substituted sulfur(vi) compounds |
| TW202304457A (zh) | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
| MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
| AU2022245277B8 (en) | 2021-03-26 | 2025-08-07 | Astrazeneca Ab | Combination treatments for melanoma |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| IT202100021863A1 (it) | 2021-08-13 | 2023-02-13 | Univ Degli Studi Milano | Morfolino pirimidine per l’uso nella prevenzione e/o nel trattamento di stati di ipereccitabilità neuronale |
| WO2023039573A1 (en) * | 2021-09-10 | 2023-03-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compounds for targeted degradation of taf1 |
| CN116283960A (zh) * | 2021-12-21 | 2023-06-23 | 上海安诺达生物科技有限公司 | 取代的稠杂环化合物及其制备方法与应用 |
| WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
| CA3240724A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
| TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
| US20250352539A1 (en) | 2022-06-15 | 2025-11-20 | Astrazeneca Ab | Combination therapy for treating cancer |
| KR20250116727A (ko) | 2022-12-06 | 2025-08-01 | 아스트라제네카 아베 | Polq 저해제 |
| JPWO2024214685A1 (https=) | 2023-04-10 | 2024-10-17 | ||
| AU2024251689A1 (en) | 2023-04-14 | 2025-11-27 | Astrazeneca Ab | Combinations of kras inhibitor and atr inhibitor for the treatment of cancer |
| CN117652610B (zh) * | 2023-10-26 | 2025-12-02 | 广东省农业科学院农业生物基因研究中心 | 一种利用3-甲基吗啉-吡啶-嘧啶衍生物抑制黄曲霉毒素产生的方法 |
| WO2025181153A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
| TW202547478A (zh) | 2024-05-31 | 2025-12-16 | 瑞典商阿斯特捷利康公司 | Ｐｏｌｑ抑制劑 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
| CA2280930C (en) | 1997-02-12 | 2010-04-06 | The Regents Of The University Of Michigan | Protein markers for lung cancer and use thereof |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| JP3663382B2 (ja) | 2000-02-15 | 2005-06-22 | スージェン・インコーポレーテッド | ピロール置換２−インドリノン蛋白質キナーゼ阻害剤 |
| KR100774855B1 (ko) | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| CN1473156A (zh) | 2000-11-10 | 2004-02-04 | - | 嘧啶衍生物及其作为神经肽y受体配体的用途 |
| EA013811B1 (ru) | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| WO2005000404A2 (en) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2006124662A1 (en) | 2005-05-13 | 2006-11-23 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| AU2006313456B2 (en) | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| DE102005024494A1 (de) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
| JP5054004B2 (ja) * | 2005-07-01 | 2012-10-24 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としてのピリミジン置換ベンゾイミダゾール誘導体 |
| CA2617042A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| WO2007027855A2 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
| JP4531027B2 (ja) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| ZA200802685B (en) | 2005-09-30 | 2009-10-28 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| KR101487027B1 (ko) | 2005-09-30 | 2015-01-28 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体 |
| WO2007063868A1 (ja) | 2005-11-29 | 2007-06-07 | Toray Industries, Inc. | アリールメチレンウレア誘導体及びその用途 |
| GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525083D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| EP1979325A1 (en) * | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR20080110998A (ko) | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Ｊａｋ２ 조절자로서 ４아릴２아미노피리미딘 또는 4아릴２아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
| EP2008210A1 (en) | 2006-03-15 | 2008-12-31 | Csir | Modulation of phosphoryl transferase activity of glutamine synthetase |
| JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
| EP2003131A4 (en) | 2006-04-04 | 2009-12-16 | Taisho Pharmaceutical Co Ltd | AMINOPYRROLIDINE COMPOUND |
| AU2007240496A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of CDC7 |
| JP5225076B2 (ja) | 2006-04-27 | 2013-07-03 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体の医薬用途 |
| GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| EP2057129A1 (en) | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| AU2007287428B2 (en) | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2008047307A1 (en) * | 2006-10-16 | 2008-04-24 | Gpc Biotech Inc. | Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors |
| EP2146981A1 (en) | 2007-04-12 | 2010-01-27 | F. Hoffmann-Roche AG | Pharmaceutical compounds |
| BRPI0814503A2 (pt) * | 2007-07-09 | 2017-05-16 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica |
| CN102282142A (zh) * | 2008-11-14 | 2011-12-14 | 拜耳先灵制药股份公司 | 取代的芳族化合物和它们的用途 |
| US20110053923A1 (en) * | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
-
2011
- 2011-06-08 SA SA111320519A patent/SA111320519B1/ar unknown
- 2011-06-09 PE PE2012002373A patent/PE20130306A1/es active IP Right Grant
- 2011-06-09 KR KR1020137000590A patent/KR101820996B1/ko active Active
- 2011-06-09 US US13/156,684 patent/US8252802B2/en active Active
- 2011-06-09 CN CN201180039088.2A patent/CN103068391B/zh active Active
- 2011-06-09 SG SG2012086112A patent/SG185711A1/en unknown
- 2011-06-09 WO PCT/GB2011/051074 patent/WO2011154737A1/en not_active Ceased
- 2011-06-09 PT PT117254946T patent/PT2579877E/pt unknown
- 2011-06-09 ES ES11725494.6T patent/ES2514325T3/es active Active
- 2011-06-09 UY UY0001033440A patent/UY33440A/es not_active Application Discontinuation
- 2011-06-09 SI SI201130280T patent/SI2579877T1/sl unknown
- 2011-06-09 RS RSP20140534 patent/RS53566B1/sr unknown
- 2011-06-09 CA CA2800203A patent/CA2800203C/en active Active
- 2011-06-09 EA EA201201680A patent/EA022087B1/ru not_active IP Right Cessation
- 2011-06-09 PL PL11725494T patent/PL2579877T3/pl unknown
- 2011-06-09 DK DK11725494.6T patent/DK2579877T3/da active
- 2011-06-09 TW TW100120242A patent/TWI526208B/zh active
- 2011-06-09 HR HRP20140953AT patent/HRP20140953T1/hr unknown
- 2011-06-09 MX MX2012014477A patent/MX2012014477A/es active IP Right Grant
- 2011-06-09 MY MYPI2012701121A patent/MY158193A/en unknown
- 2011-06-09 PH PH1/2012/502438A patent/PH12012502438A1/en unknown
- 2011-06-09 NZ NZ604480A patent/NZ604480A/en unknown
- 2011-06-09 AU AU2011263491A patent/AU2011263491B2/en active Active
- 2011-06-09 BR BR112012031561A patent/BR112012031561B1/pt active IP Right Grant
- 2011-06-09 EP EP11725494.6A patent/EP2579877B1/en active Active
- 2011-06-09 JP JP2013513758A patent/JP5721821B2/ja active Active
- 2011-06-10 AR ARP110102022A patent/AR081859A1/es active IP Right Grant
- 2011-09-06 CU CU20120169A patent/CU24109B1/es active IP Right Grant
- 2011-09-06 UA UAA201215028A patent/UA109010C2/en unknown
-
2012
- 2012-07-02 US US13/540,057 patent/US8552004B2/en active Active
- 2012-12-11 NI NI201200184A patent/NI201200184A/es unknown
- 2012-12-11 DO DO2012000310A patent/DOP2012000310A/es unknown
- 2012-12-11 CR CR20120628A patent/CR20120628A/es unknown
- 2012-12-11 CO CO12224297A patent/CO6640270A2/es active IP Right Grant
- 2012-12-11 CL CL2012003503A patent/CL2012003503A1/es unknown
- 2012-12-11 GT GT201200334A patent/GT201200334A/es unknown
- 2012-12-11 EC ECSP12012334 patent/ECSP12012334A/es unknown
-
2013
- 2013-01-10 ZA ZA2013/00255A patent/ZA201300255B/en unknown
- 2013-09-18 US US14/030,134 patent/US8999997B2/en active Active
-
2014
- 2014-10-09 SM SM201400146T patent/SMT201400146B/xx unknown
-
2015
- 2015-02-26 US US14/631,961 patent/US9155742B2/en active Active
- 2015-09-21 US US14/859,567 patent/US9421213B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528204A5 (https=) | ||
| USRE49556E1 (en) | Compounds and compositions as protein kinase inhibitors | |
| HRP20140953T1 (hr) | Morfolino pirimidini i njihova uporaba za lijeäśenje | |
| JP6060163B2 (ja) | キナーゼインヒビターとしてのベンゾニトリル誘導体 | |
| JP2014523851A5 (https=) | ||
| JP2015518894A5 (https=) | ||
| JP2011522866A5 (https=) | ||
| JP2014139226A5 (https=) | ||
| JP2016523974A5 (https=) | ||
| JP2014526549A5 (https=) | ||
| JP2014505735A5 (https=) | ||
| JP2011500806A5 (https=) | ||
| JP2017502940A5 (https=) | ||
| RU2014151009A (ru) | Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы | |
| JP2016533366A5 (https=) | ||
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2016538313A5 (https=) | ||
| JP2014504646A5 (https=) | ||
| JP2017504635A5 (https=) | ||
| JP2013528640A5 (https=) | ||
| JP2009515814A5 (https=) | ||
| JP2013523814A5 (https=) | ||
| JP2014510147A5 (https=) | ||
| RU2012130929A (ru) | Гетероциклические соединения в качестве ингибиторов янус-киназы | |
| JP2019505594A5 (https=) |